211 related articles for article (PubMed ID: 33677931)
21. Clinical impact of the detection of BRAF mutations in thyroid pathology: potential usefulness as diagnostic, prognostic and theragnostic applications.
Lassalle S; Hofman V; Ilie M; Butori C; Bozec A; Santini J; Vielh P; Hofman P
Curr Med Chem; 2010; 17(17):1839-50. PubMed ID: 20345340
[TBL] [Abstract][Full Text] [Related]
22. The Risk of Relapse in Papillary Thyroid Cancer (PTC) in the Context of BRAFV600E Mutation Status and Other Prognostic Factors.
Czarniecka A; Kowal M; Rusinek D; Krajewska J; Jarzab M; Stobiecka E; Chmielik E; Zembala-Nozynska E; Poltorak S; Sacher A; Maciejewski A; Zebracka-Gala J; Lange D; Oczko-Wojciechowska M; Handkiewicz-Junak D; Jarzab B
PLoS One; 2015; 10(7):e0132821. PubMed ID: 26177218
[TBL] [Abstract][Full Text] [Related]
23. BRAF analysis by fine needle aspiration biopsy of thyroid nodules improves preoperative identification of papillary thyroid carcinoma and represents a prognostic factor. A mono-institutional experience.
Pelizzo MR; Boschin IM; Barollo S; Pennelli G; Toniato A; Zambonin L; Vianello F; Piotto A; Ide EC; Pagetta C; Sorgato N; Torresan F; Girelli ME; Nacamulli D; Mantero F; Mian C
Clin Chem Lab Med; 2011 Feb; 49(2):325-9. PubMed ID: 21175381
[TBL] [Abstract][Full Text] [Related]
24. Clinical and pathological features and the BRAF(V600E) mutation in patients with papillary thyroid carcinoma with and without concurrent Hashimoto thyroiditis.
Kim SK; Song KH; Lim SD; Lim YC; Yoo YB; Kim JS; Hwang TS
Thyroid; 2009 Feb; 19(2):137-41. PubMed ID: 19014278
[TBL] [Abstract][Full Text] [Related]
25. Possible involvement of BRAFV600E in altered gene expression in papillary thyroid cancer.
Watanabe R; Hayashi Y; Sassa M; Kikumori T; Imai T; Kiuchi T; Murata Y
Endocr J; 2009; 56(3):407-14. PubMed ID: 19194051
[TBL] [Abstract][Full Text] [Related]
26. Stomatin-like protein 2 overexpression in papillary thyroid carcinoma is significantly associated with high-risk clinicopathological parameters and BRAFV600E mutation.
Bartolome A; Boskovic S; Paunovic I; Bozic V; Cvejic D
APMIS; 2016 Apr; 124(4):271-7. PubMed ID: 26750533
[TBL] [Abstract][Full Text] [Related]
27. BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications.
Xing M
Endocr Rev; 2007 Dec; 28(7):742-62. PubMed ID: 17940185
[TBL] [Abstract][Full Text] [Related]
28. Lack of association of BRAF mutation with negative prognostic indicators in papillary thyroid carcinoma: the University of California, San Francisco, experience.
Gouveia C; Can NT; Bostrom A; Grenert JP; van Zante A; Orloff LA
JAMA Otolaryngol Head Neck Surg; 2013 Nov; 139(11):1164-70. PubMed ID: 24030686
[TBL] [Abstract][Full Text] [Related]
29. BRAFV600E mutation and X-linked inhibitor of apoptosis expression in papillary thyroid carcinoma.
Gu LQ; Li FY; Zhao L; Liu Y; Zang XX; Wang TX; Chen HP; Ning G; Zhao YJ
Thyroid; 2009 Apr; 19(4):347-54. PubMed ID: 19355825
[TBL] [Abstract][Full Text] [Related]
30. Midkine expression is associated with clinicopathological features and BRAF mutation in papillary thyroid cancer.
Shao H; Yu X; Wang C; Wang Q; Guan H
Endocrine; 2014 Jun; 46(2):285-91. PubMed ID: 24272599
[TBL] [Abstract][Full Text] [Related]
31. Association Between Obesity and BRAFV600E Mutation Status in Patients with Papillary Thyroid Cancer.
Lee J; Lee CR; Ku CR; Kang SW; Jeong JJ; Shin DY; Nam KH; Jung SG; Lee EJ; Chung WY; Jo YS
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S683-90. PubMed ID: 26215201
[TBL] [Abstract][Full Text] [Related]
32. The thyroid imaging reporting and data system on US, but not the BRAFV600E mutation in fine-needle aspirates, is associated with lateral lymph node metastasis in PTC.
Park VY; Kim EK; Moon HJ; Yoon JH; Kwak JY
Medicine (Baltimore); 2016 Jul; 95(29):e4292. PubMed ID: 27442672
[TBL] [Abstract][Full Text] [Related]
33. BRAF
Shi C; Cao J; Shi T; Liang M; Ding C; Lv Y; Zhang W; Li C; Gao W; Wu G; Man J
World J Surg Oncol; 2020 Jun; 18(1):145. PubMed ID: 32593310
[TBL] [Abstract][Full Text] [Related]
34. In papillary thyroid carcinoma BRAFV600E is associated with increased expression of the urokinase plasminogen activator and its cognate receptor, but not with disease-free interval.
Ulisse S; Baldini E; Sorrenti S; Barollo S; Prinzi N; Catania A; Nesca A; Gnessi L; Pelizzo MR; Mian C; De Vito C; Calvanese A; Palermo S; Persechino S; De Antoni E; D'Armiento M
Clin Endocrinol (Oxf); 2012 Nov; 77(5):780-6. PubMed ID: 22702340
[TBL] [Abstract][Full Text] [Related]
35. The expression profile of integrin receptors and osteopontin in thyroid malignancies varies depending on the tumor progression rate and presence of BRAF V600E mutation.
Chernaya G; Mikhno N; Khabalova T; Svyatchenko S; Mostovich L; Shevchenko S; Gulyaeva L
Surg Oncol; 2018 Dec; 27(4):702-708. PubMed ID: 30449496
[TBL] [Abstract][Full Text] [Related]
36. MicroRNA-150-5p affects cell proliferation, apoptosis, and EMT by regulation of the BRAF
Yan R; Yang T; Zhai H; Zhou Z; Gao L; Li Y
J Cell Biochem; 2018 Nov; 119(11):8763-8772. PubMed ID: 30126001
[TBL] [Abstract][Full Text] [Related]
37. BRAF-activated WT1 contributes to cancer growth and regulates autophagy and apoptosis in papillary thyroid carcinoma.
Chen X; Lin S; Lin Y; Wu S; Zhuo M; Zhang A; Zheng J; You Z
J Transl Med; 2022 Feb; 20(1):79. PubMed ID: 35123502
[TBL] [Abstract][Full Text] [Related]
38. BRAF V600E mutation is associated with tumor aggressiveness in papillary thyroid cancer.
Kim SJ; Lee KE; Myong JP; Park JH; Jeon YK; Min HS; Park SY; Jung KC; Koo do H; Youn YK
World J Surg; 2012 Feb; 36(2):310-7. PubMed ID: 22190222
[TBL] [Abstract][Full Text] [Related]
39. The expression of monocarboxylate transporters in thyroid carcinoma can be associated with the morphological features of BRAF
Rossi ED; Bizzarro T; Granja S; Martini M; Capodimonti S; Luca E; Fadda G; Lombardi CP; Pontecorvi A; Larocca LM; Baltazar F; Schmitt F
Endocrine; 2017 May; 56(2):379-387. PubMed ID: 27484771
[TBL] [Abstract][Full Text] [Related]
40. LIMD2 Is Overexpressed in BRAF V600E-Positive Papillary Thyroid Carcinomas and Matched Lymph Node Metastases.
Pinheiro Dos Santos MJC; Bastos AU; da Costa VR; Delcelo R; Lindsey SC; Colozza-Gama GA; Peng H; Rauscher FJ; Oler G; Cerutti JM
Endocr Pathol; 2018 Sep; 29(3):222-230. PubMed ID: 29560564
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
